ClinicalTrials.gg
CompletedNCT05507515Updated Apr 9, 2024

A Phase 1 Study of ONO-2020 in Healthy Participants

A Phase 1 interventional study of ONO-2020 and Placebo in Healthy Volunteers, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 55 years of age (Parts A, B, C, and E) or ≥65 years of age (Part D) inclusive at the time of .
  2. Male and female participants of non-Japanese ethnicity (Parts A, B, C, and D) or of Japanese ethnicity (Part E).
  3. No medical history and no abnormal physical examination, laboratory profiles, vital signs or abnormalities, based on the Screening examination.
  4. of ≥18.5 to \<30 kg/m2, and a body weight of at least 50 kg for males and 45 kg for females to a maximum of 100 kg, at the time of Screening.
  5. Agree to use an effective method of .
  6. Able and willing to give informed consent after reading the information and consent form and after having the opportunity to discuss the study with the Investigator or designee.
  7. Estimated (CrCL, Cockcroft-Gault equation) ≥90 mL/min at Screening. In Part D only, an estimated ≥60 mL/min at Screening.
  8. Fully vaccinated for SARS-CoV-2 (received primary series of COVID-19 vaccine) prior to Screening.

Exclusion criteria

Exclusion Criteria:

  1. Mentally or legally incapacitated or has significant emotional problems at the time of the Screening visit or expected during the conduct of the study.
  2. History or presence of medical, surgical or psychiatric condition or disease that in the opinion of the Investigator or Sponsor Medical Monitor might confound the results of the study or pose an additional risk to the participant by their participation in the study.
  3. or idiosyncratic reaction to the study interventions, or related compounds, or severe food allergies.
  4. alcoholism or drug/chemical/substance abuse within the past 2 years prior to the first dosing.
  5. Use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements, including St. John's Wort, within 14 days or five half-lives (whichever is longer) of first dosing and throughout the study.
  6. Use of any drugs known to be significant inducers or inhibitors of cytochrome P450 (CYP) enzymes and/or drug transporter substrates for 28 days prior to the first dosing and throughout the study.
  7. Participation in another clinical study within 120 days (or five half-lives of the study intervention, whichever is longer) prior to the first dosing.
  8. Liver function test values are in the abnormal range before inclusion.
  9. Positive urine drug, alcohol, or cotinine results at Screening or check in.
  10. Positive results at Screening for active viral infection that include , , , and SARS-CoV-2.
  11. Seated resting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at Screening.
  12. Seated resting pulse rate is lower than 40 beats per minute (bpm) or higher than 100 bpm at Screening.
  13. Clinically significant history or presence of findings.
  14. The participant is a current smoker or has smoked within 3 months of Screening or has a positive urine cotinine at Screening or admission.
  15. Female who is pregnant or lactating.
  16. Donation of blood or significant blood loss of 400 mL or more within 90 days prior to the first dosing, or blood donation of 200 mL or more within 30 days prior to the first dosing, or blood plasma or donation within 14 days prior to the first dosing, or blood transfusion within 90 days prior to the first dosing.
  17. Participants who, in the opinion of the Investigator, are considered unsuitable for any other reason.

    Exclusion criteria, applicable to all participants taking part in the food effect Cohort in Part A:

  18. Participants who are vegetarian or vegan or not willing to eat a high-fat breakfast.

    Exclusion criteria, applicable to all participants undergoing lumbar puncture for CSF collection (Part C):

  19. History of significant back pain, significant kyphosis, and or scoliosis or other spinal column deformities.
  20. History of poor venous access.
  21. History of hypersensitivity for local anesthetics (Lidocaine).
  22. History or evidence or fundoscopic findings suggestive of raised intracranial pressure.
  23. History or evidence of laboratory abnormalities for coagulation parameters or the use of medications that may increase the risk of bleeding.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    Part A: Cohort A1 ONO-2020 or Placebo - fasted

    Single ascending doses of ONO-2020 orally under fasted conditions

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part A: Cohort A2 ONO-2020 or Placebo - fasted and fed

    Single ascending doses of ONO-2020 orally under fasted and fed conditions

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part A: Cohort A3 ONO-2020 or Placebo - fasted

    Single ascending doses of ONO-2020 orally under fasted conditions

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part A: Cohort A4 ONO-2020 or Placebo - fasted and fed

    Single ascending doses of ONO-2020 orally under fasted and fed conditions

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part A: Cohort A5 ONO-2020 or Placebo - fasted

    Single ascending doses of ONO-2020 orally under fasted conditions

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part A: Cohort A6 ONO-2020 or Placebo - fasted

    Single ascending doses of ONO-2020 orally under fasted conditions

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part B: Cohort B1 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part B: Cohort B2 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part B: Cohort B3 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part B: Cohort B4 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part B: Cohort B5 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part C: Cohort C1 ONO-2020

    Single dose of ONO-2020 orally for CSF sampling

    Drug: ONO-2020

  • Experimental
    Part C: Cohort C2 ONO-2020

    Single dose of ONO-2020 orally for CSF sampling

    Drug: ONO-2020

  • Experimental
    Part D: Cohort D1 ONO-2020 or Placebo

    Single dose of ONO-2020 orally in elderly healthy volunteers

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part E: Cohort E1 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers

    Drug: ONO-2020 · Drug: Placebo

  • Experimental
    Part E: Cohort E2 ONO-2020 or Placebo

    Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers

    Drug: ONO-2020 · Drug: Placebo

Interventions

  • ONO-2020 tablets

  • DrugPlacebo

    Placebo tablets matching ONO-2020 tablets

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and type of treatment emergent adverse events (TEAEs)

    Incidence of TEAEs will be summarized overall, and by study part and dose group using frequency and percentage.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  2. Vital signs (blood pressure)

    Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  3. Vital signs (pulse rate)

    Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  4. Vital signs (body temperature)

    Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  5. Vital signs (respiratory rate)

    Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  6. 12-lead electrocardiograms (ECGs) parameters, such as but not limited to heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)

    The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of ECG results will be tabulated at each time point.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  7. Clinically significant abnormal telemetry electrocardiograms (ECGs)

    The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of telemetry ECGs results will be tabulated at each time point.

    Time frame: Part A and D: Day 1

  8. Clinically significant abnormal physical examination findings

    The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of physical examination results will be tabulated at each time point.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  9. Clinical laboratory abnormalities (hematology, clinical chemistry, coagulation, and urinalysis)

    The number and percentage of subjects with abnormal laboratory results at any time during the study will be tabulated.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  10. Ophthalmologic examination findings (pupil size and pupillary light reflex)

    The number and percentage of subjects with miosis will be summarized by laterality at each time point.

    Time frame: Part A, C and D: From Day 1 up to Day 7, Part B and E: From Day 1 up to Day 21

  11. Clinically abnormal findings in Mini-International Neuropsychiatric Interview Screen (M.I.N.I.-Screen)

    Responses to the M.I.N.I.-Screen will be listed.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

  12. Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)

    Responses to the suicidality assessment scale (C-SSRS) will be listed.

    Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21

Secondary outcomes

  1. Pharmacokinetics (Cmax in plasma)

    Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19

  2. Pharmacokinetics (Tmax in plasma)

    Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19

  3. Pharmacokinetics (AUClast in plasma)

    Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19

  4. Pharmacokinetics (AUCinf in plasma)

    Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19

  5. Pharmacokinetics (T1/2 in plasma)

    Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19

  6. Pharmacokinetics (CL/F in plasma)

    Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19

  7. Pharmacokinetics (Aet in urine)

    Time frame: Part A and D: Day 1 through Day 4

  8. Pharmacokinetics (fe/F in urine)

    Time frame: Part A and D: Day 1 through Day 4

  9. Pharmacokinetics (CLR in urine)

    Time frame: Part A and D: Day 1 through Day 4

  10. Pharmacokinetics (Ctrough in plasma)

    Time frame: Part B and E: Day 2 through Day 13

  11. Pharmacokinetics (ONO-2020 concentration in CSF)

    Time frame: Part C: Day 2

07

Study locations

1 site
  • Altasciences
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 19, 2022
StartActual
Jul 29, 2022
Primary completionActual
Dec 24, 2023
CompletionActual
Dec 24, 2023
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05507515
Responsible party
Sponsor
First posted
Aug 19, 2022
Start date
Jul 29, 2022
Primary completion
Dec 24, 2023
Completion
Dec 24, 2023
Last update
Apr 9, 2024

Study contacts

Project Leader
study director · Ono Pharma USA Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-2020

Start the discussion